← Leaderboards
Jennifer S Yokoyama
University Of California, San Francisco
$12,164,952
Attributed
$14,441,467
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5M · FY2015–25$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$23,473,734 · 11
By mechanism
U54$10,614,886 · 3
R01$6,679,633 · 2
P30$2,637,574 · 2
P01$1,475,348 · 1
U19$1,097,250 · 1
K01$647,668 · 1
Top collaborators
- David A Agard5 shared
- Nilton Custodio5 shared
- Agustin M. Ibanez5 shared
- Aimee Kao5 shared
- Celeste Marie Karch5 shared
- Bruce L Miller5 shared
- Katherine Laurel Possin5 shared
- Francisco Lopera4 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Martin Kampmann$17,201,095
- Lawren Vandevrede$1,005,750
- Aimee Kao$26,280,041
- Agustin M. Ibanez$3,683,664
- Sam C. Wang$4,494,981
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposGenomicsGenetic RiskGeneticS DiseaseNerve DegenerationGenesPathway InteractionsNeurodegenerative DisordersTranscriptomicsNeuropathologyFrontotemporal DementiaFutureMutationSamplingInnovationLinkCohortPolygenic Risk ScoreTau ProteinsBiological MarkersImagePathogenicityProteins
Grant awards (37)
Tau Metabolism in FTD: From Gene Mutations to Molecular Chaperones and Lysosomal Proteases$1,806,742
U54 · FY2025 · NS
Core G - Biomarker Core$663,704
P30 · FY2025 · AG · contact PI
Genetics$541,718
P01 · FY2025 · AG · contact PI
Project 2: Biomarker Analysis, Non-Genetic Risk Factors, and Their Genetic Interactions$310,488
U19 · FY2025 · AG · contact PI
Core C: Genomics and Transcriptomics$305,424
U54 · FY2025 · NS · contact PI
Tau Metabolism in FTD: From Gene Mutations to Molecular Chaperones and Lysosomal Proteases$1,806,742
U54 · FY2024 · NS
Core G - Biomarker Core$775,233
P30 · FY2024 · AG · contact PI
US-South American Initiative for Genetic-Neural-Behavioral Interactions in Human Neurodegenerative Research$480,355
R01 · FY2024 · AG
Genetics$454,386
P01 · FY2024 · AG · contact PI
Project 2: Biomarker Analysis, Non-Genetic Risk Factors, and Their Genetic Interactions$369,938
U19 · FY2024 · AG · contact PI
Core C: Genomics and Transcriptomics$305,424
U54 · FY2024 · NS · contact PI
Tau Metabolism in FTD: From Gene Mutations to Molecular Chaperones and Lysosomal Proteases$1,806,742
U54 · FY2023 · NS
Elucidating clinical heterogeneity in early-onset AD via genomics, transcriptomics, and neuroimaging$807,400
R01 · FY2023 · AG · contact PI
Core G: Biomarker Core$604,677
P30 · FY2023 · AG · contact PI
US-South American Initiative for Genetic-Neural-Behavioral Interactions in Human Neurodegenerative Research$512,850
R01 · FY2023 · AG
Genetics$479,244
P01 · FY2023 · AG · contact PI
Project 2: Biomarker Analysis, Non-Genetic Risk Factors, and Their Genetic Interactions$416,824
U19 · FY2023 · AG · contact PI
Core C: Genomics and Transcriptomics$363,863
U54 · FY2023 · NS · contact PI
Tau Metabolism in FTD: From Gene Mutations to Molecular Chaperones and Lysosomal Proteases$1,803,439
U54 · FY2022 · NS
Elucidating clinical heterogeneity in early-onset AD via genomics, transcriptomics, and neuroimaging$807,369
R01 · FY2022 · AG · contact PI
Core G: Biomarker Core$593,960
P30 · FY2022 · AG · contact PI
Core C: Genomics and Transcriptomics$301,386
U54 · FY2022 · NS · contact PI
Tau Metabolism in FTD: From Gene Mutations to Molecular Chaperones and Lysosomal Proteases$1,808,602
U54 · FY2021 · NS
Elucidating clinical heterogeneity in early-onset AD via genomics, transcriptomics, and neuroimaging$807,369
R01 · FY2021 · AG · contact PI
US-South American Initiative for Genetic-Neural-Behavioral Interactions in Human Neurodegenerative Research$521,480
R01 · FY2021 · AG
Core C: Genomics and Transcriptomics$306,522
U54 · FY2021 · NS · contact PI
US-South American Initiative for Genetic-Neural-Behavioral Interactions in Human Neurodegenerative Research$807,005
R01 · FY2020 · AG
Elucidating clinical heterogeneity in early-onset AD via genomics, transcriptomics, and neuroimaging$806,995
R01 · FY2020 · AG · contact PI
Sex in Alzheimer disease$161,000
R03 · FY2020 · AG · contact PI
Elucidating clinical heterogeneity in early-onset AD via genomics, transcriptomics, and neuroimaging$794,566
R01 · FY2019 · AG · contact PI
US-South American Initiative for Genetic-Neural-Behavioral Interactions in Human Neurodegenerative Research$334,244
R01 · FY2019 · AG
Sex in Alzheimer disease$160,375
R03 · FY2019 · AG · contact PI
RNA signatures of frontotemporal dementia and ALS due to C9ORF72 expansion$129,600
K01 · FY2019 · AG · contact PI
RNA signatures of frontotemporal dementia and ALS due to C9ORF72 expansion$129,600
K01 · FY2018 · AG · contact PI
RNA signatures of frontotemporal dementia and ALS due to C9ORF72 expansion$129,600
K01 · FY2017 · AG · contact PI
RNA signatures of frontotemporal dementia and ALS due to C9ORF72 expansion$129,472
K01 · FY2016 · AG · contact PI
RNA signatures of frontotemporal dementia and ALS due to C9ORF72 expansion$129,396
K01 · FY2015 · AG · contact PI